Worldquant Millennium Advisors LLC Acquires 76,809 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Worldquant Millennium Advisors LLC lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 230.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 110,196 shares of the company's stock after buying an additional 76,809 shares during the quarter. Worldquant Millennium Advisors LLC owned approximately 0.13% of IDEXX Laboratories worth $55,673,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Chicago Partners Investment Group LLC grew its stake in IDEXX Laboratories by 16.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after acquiring an additional 96 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in IDEXX Laboratories by 13.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock valued at $5,825,000 after purchasing an additional 1,453 shares during the period. National Pension Service grew its position in shares of IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after buying an additional 12,647 shares in the last quarter. EFG Asset Management Americas Corp. grew its holdings in IDEXX Laboratories by 45.3% during the 2nd quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock worth $6,201,000 after acquiring an additional 3,966 shares in the last quarter. Finally, Larson Financial Group LLC raised its holdings in shares of IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after purchasing an additional 2,241 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded up $8.20 during trading hours on Friday, reaching $435.69. The company's stock had a trading volume of 551,918 shares, compared to its average volume of 649,999. The company's 50-day moving average is $445.99 and its two-hundred day moving average is $475.13. The stock has a market cap of $35.68 billion, a PE ratio of 42.01, a PEG ratio of 3.97 and a beta of 1.37. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. During the same quarter in the previous year, the business earned $2.53 EPS. The company's quarterly revenue was up 6.6% compared to the same quarter last year. Analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IDXX. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, November 28th. JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Barclays reduced their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $546.56.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company's stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.